Edition:
United Kingdom

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

25,838.94ZAc
23 Jan 2018
Change (% chg)

388.94 (+1.53%)
Prev Close
25,450.00
Open
25,610.00
Day's High
25,916.00
Day's Low
25,600.00
Volume
1,097,642
Avg. Vol
1,508,215
52-wk High
32,750.00
52-wk Low
23,498.00

Select another date:

Mon, Jan 15 2018

BRIEF-Aspen Pharmacare Receives Approval For Registration Of Alula In China​

* ‍ASPEN RECEIVES APPROVAL FOR REGISTRATION OF ALULA IN CHINA​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Aspen Pharmacare Says Has Had No Contact With Viceroy Research

* HAS HAD NO CONTACT WITH VICEROY RESEARCH AND, AS SUCH, IS UNABLE TO CONFIRM THAT SPECULATION IS CORRECT

UK anti-trust regulator investigates South Africa's Aspen Pharmacare

JOHANNESBURG Britain's competition regulator has launched an investigation into Africa's biggest generic drug maker Aspen Pharmacare over alleged anticompetitive conduct in the supply of blood pressure and arthritis drugs, Aspen said on Friday.

UK anti-trust regulator investigates South Africa's Aspen Pharmacare

JOHANNESBURG Britain's competition regulator has launched an investigation into Africa's biggest generic drug maker Aspen Pharmacare over alleged anticompetitive conduct in the supply of blood pressure and arthritis drugs, Aspen said on Friday.

UK anti-trust regulator investigates S.Africa's Aspen Pharmacare

JOHANNESBURG, Oct 13 Britain's competition regulator has launched an investigation into Africa's biggest generic drug maker Aspen Pharmacare over alleged anticompetitive conduct in the supply of blood pressure and arthritis drugs, Aspen said on Friday.

BRIEF-Aspen Pharmacare Holdings ‍welcomes SA Competition Commission’s decision not to refer complaint about Aspen

* ‍WELCOMES SOUTH AFRICAN COMPETITION COMMISSION'S DECISION TO DROP ITS INVESTIGATION OF ASPEN FOR SUSPECTED ABUSE OF DOMINANCE AND EXCESSIVE PRICING Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

UPDATE 2-Aspen Pharmacare shifts the needle to injectibles

JOHANNESBURG, Sept 14 South Africa's Aspen Pharmacare expanded its anaesthetic drugs portfolio with a $766 million deal with AstraZeneca as it focuses on injectibles rather than making tablets.

South Africa's Aspen Pharmacare posts 46 pct profit jump

JOHANNESBURG, Sept 14 South Africa's Aspen Pharmacare reported a 46 percent rise in full-year profit, buoyed by a revenue boost from an anaesthetics portfolio acquired from AstraZeneca and GlaxoSmithKline, the company said on Thursday.

BRIEF-Aspen Pharmacare Holdings posts FY revenue 41,2 bln rand

* RAISED NORMALISED HEADLINE EARNINGS PER SHARE ("NHEPS") BY 16% TO 1 463 CENTS IN YEAR ENDED 30 JUNE 2017.

CORRECTED-South Africa's Aspen Pharmacare flags jump in full-year profit

JOHANNESBURG, Aug 30 South African drugmaker Aspen Pharmacare said on Wednesday that it expects full-year profit to climb by as much as 48 percent from last year when it was hit by a writedown on its Venezuelan business.

Select another date: